These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 25269730)

  • 1. Development of EMA401 as an orally-administered, highly-selective angiotensin II type 2 receptor antagonist for the treatment of neuropathic pain.
    McCarthy T
    J Peripher Nerv Syst; 2014 Oct; 19 Suppl 2():S13-4. PubMed ID: 25269730
    [No Abstract]   [Full Text] [Related]  

  • 2. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial.
    Rice ASC; Dworkin RH; McCarthy TD; Anand P; Bountra C; McCloud PI; Hill J; Cutter G; Kitson G; Desem N; Raff M;
    Lancet; 2014 May; 383(9929):1637-1647. PubMed ID: 24507377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II type 2-receptor: new clinically validated target in the treatment of neuropathic pain.
    Rice AS; Smith MT
    Clin Pharmacol Ther; 2015 Feb; 97(2):128-30. PubMed ID: 25670516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy.
    Rice ASC; Dworkin RH; Finnerup NB; Attal N; Anand P; Freeman R; Piaia A; Callegari F; Doerr C; Mondal S; Narayanan N; Ecochard L; Flossbach Y; Pandhi S
    Pain; 2021 Oct; 162(10):2578-2589. PubMed ID: 33675631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats.
    Smith MT; Wyse BD; Edwards SR
    Pain Med; 2013 May; 14(5):692-705. PubMed ID: 23489258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drug treatment reduces chronic pain following shingles.
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):180-1. PubMed ID: 25011130
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective small molecule angiotensin II type 2 receptor antagonists for neuropathic pain: preclinical and clinical studies.
    Smith MT; Anand P; Rice ASC
    Pain; 2016 Feb; 157 Suppl 1():S33-S41. PubMed ID: 26785154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-clinical characterization of the disposition of EMA401, a novel small molecule angiotensin II type 2 receptor (AT2R) antagonist.
    Murgasova R; Carreras ET; Suetterlin-Hachmann M; da Silva Torrao LR; Kittelmann M; Alexandra V; Fredenhagen A
    Biopharm Drug Dispos; 2020 Apr; 41(4-5):166-183. PubMed ID: 32190910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting angiotensin II type 2 receptor pathways to treat neuropathic pain and inflammatory pain.
    Smith MT; Muralidharan A
    Expert Opin Ther Targets; 2015 Jan; 19(1):25-35. PubMed ID: 25315162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II: from blood pressure to pain control.
    Finnerup NB; Baastrup C
    Lancet; 2014 May; 383(9929):1613-1614. PubMed ID: 24507378
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of pregabalin on pain-related sleep interference in diabetic peripheral neuropathy or postherpetic neuralgia: a review of nine clinical trials.
    Roth T; van Seventer R; Murphy TK
    Curr Med Res Opin; 2010 Oct; 26(10):2411-9. PubMed ID: 20812792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia.
    Irving GA; Backonja MM; Dunteman E; Blonsky ER; Vanhove GF; Lu SP; Tobias J;
    Pain Med; 2011 Jan; 12(1):99-109. PubMed ID: 21087403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II type 2 receptor signalling as a pain target: Bench, bedside and back-translation.
    Shepherd AJ; Rice AS; Smith MT
    Curr Opin Pharmacol; 2023 Dec; 73():102415. PubMed ID: 38041933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.
    Backonja M; Wallace MS; Blonsky ER; Cutler BJ; Malan P; Rauck R; Tobias J;
    Lancet Neurol; 2008 Dec; 7(12):1106-12. PubMed ID: 18977178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748).
    Zhang L; Rainka M; Freeman R; Harden RN; Bell CF; Chen C; Graff O; Harding K; Hunter S; Kavanagh S; Laurijssens B; Schwartzbach C; Warren S; McClung C
    J Pain; 2013 Jun; 14(6):590-603. PubMed ID: 23602345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of Unevoked Mechanical and Cold Pain Hypersensitivities Associated With Experimental Neuropathy in Mice by Angiotensin II Type-2 Receptor Antagonism.
    Shepherd AJ; Mohapatra DP
    Anesth Analg; 2019 Jun; 128(6):e84-e87. PubMed ID: 31094778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily gastroretentive gabapentin for postherpetic neuralgia: integrated efficacy, time to onset of pain relief and safety analyses of data from two phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Rauck RL; Irving GA; Wallace MS; Vanhove GF; Sweeney M
    J Pain Symptom Manage; 2013 Aug; 46(2):219-28. PubMed ID: 23149085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled trial of a selective COX-2 inhibitor, GW406381, in patients with postherpetic neuralgia.
    Shackelford S; Rauck R; Quessy S; Blum D; Hodge R; Philipson R
    J Pain; 2009 Jun; 10(6):654-60. PubMed ID: 19409858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia.
    Xiao L; Mackey S; Hui H; Xong D; Zhang Q; Zhang D
    Pain Med; 2010 Dec; 11(12):1827-33. PubMed ID: 21134121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia.
    Irving G; Backonja M; Rauck R; Webster LR; Tobias JK; Vanhove GF
    Clin J Pain; 2012 Feb; 28(2):101-7. PubMed ID: 21753727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.